Realcan Pharmaceutical Group Co (SZSE:002589) EV-to-EBIT : -1.32 (As of Apr. 28, 2024)

Realcan Pharmaceutical Group Co EV-to-EBIT Chart

Realcan Pharmaceutical Group Co Annual Data
	Trend	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22
EV-to-EBIT		Get a 7-Day Free Trial					7.10	19.28	9.74	7.58	-3.83

Realcan Pharmaceutical Group Co Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial															13.70	-3.83	-3.24	-2.31	-2.41

Competitive Comparison of Realcan Pharmaceutical Group Co's EV-to-EBIT

For the Medical Distribution subindustry, Realcan Pharmaceutical Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Realcan Pharmaceutical Group Co's EV-to-EBIT Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Realcan Pharmaceutical Group Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Realcan Pharmaceutical Group Co's EV-to-EBIT falls into.

Realcan Pharmaceutical Group Co EV-to-EBIT Calculation

Realcan Pharmaceutical Group Co's EV-to-EBIT for today is calculated as:

Realcan Pharmaceutical Group Co's current Enterprise Value is ¥2,080 Mil.
Realcan Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-1,582 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Realcan Pharmaceutical Group Co  (SZSE:002589) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Realcan Pharmaceutical Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Realcan Pharmaceutical Group Co's Enterprise Value for the quarter that ended in Sep. 2023 was ¥3,813 Mil.
Realcan Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-1,582 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Realcan Pharmaceutical Group Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Realcan Pharmaceutical Group Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Realcan Pharmaceutical Group Co (SZSE:002589) Business Description